Key features and details
- One-wash 90 minute protocol
- Sensitivity: 1.1 pmol/L
- Range: 2.1 pmol/L - 133.6 pmol/L
- Sample type: Hep Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman Insulin ELISA Kit
See all Insulin kits
Intra-assay Sample n Mean SD CV% Overall 5 8.6% Inter-assay Sample n Mean SD CV% Overall 3 4.9%
Sample typeSerum, Hep Plasma
Assay typeSandwich (quantitative)
Range2.1 pmol/L - 133.6 pmol/L
Sample specific recovery Sample type Average % Range Serum 106 103% - 111% Hep Plasma 112 108% - 120%
Assay time1h 30m
Assay durationOne step assay
Species reactivityReacts with: Human
Does not react with: Sheep, Goat
Abcam is committed to meeting high quality standards of ethical manufacturing and has decided to discontinue this product because it contains antibodies generated by the ascites method. We are sorry for the inconvenience this may cause. We are currently developing a replacement kit with recombinant monoclonal antibodies.
Human Insulin ELISA Kit (ab200011) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Insulin protein in hep plasma and serum. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Insulin with 1.1 pmol/L sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Insulin is a highly conserved, secreted hormone essential for glucose metabolism. Produced by pancreatic beta cells, proinsulin is proteolyzed into an A and a B chain, which form a 6 kDa mature protein. Basal levels of insulin are continuously delivered into the bloodstream, and additional levels are secreted proportional to food ingestion. Insulin secretion is highly regulated, and dysregulation of insulin production or sensitivity results in Type 1 diabetes mellitus or Type 2 diabetes mellitus, respectively.
PlatformMicroplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 10X Human Insulin Capture Antibody 1 x 600μl 10X Human Insulin Detector Antibody 1 x 600μl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 5BI 1 x 6ml Human Insulin Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml
FunctionInsulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.
Involvement in diseaseDefects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].
Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.
Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
Sequence similaritiesBelongs to the insulin family.
- Information by UniProt
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
Background-subtracted data values (mean +/- SD) are graphed.
Data shown for serum is from an individual donor with high endogenous insulin levels. Data shown for plasma is from a pooled (n=50) sample. Background-subtracted data values (mean +/- SD, n = 3) are graphed.
Ten individual healthy donors were evaluated for the presence of Insulin in serum using this assay. The range was from 11.8 – 345.1 pmol/L, with an average of 99.4 pmol/L. Health history and dietary status of donors were unknown.
ab200011 has been referenced in 3 publications.
- Li W et al. Protective effect of glycine in streptozotocin-induced diabetic cataract through aldose reductase inhibitory activity. Biomed Pharmacother 114:108794 (2019). PubMed: 30947017
- Wang Y et al. Influence of androgen on myocardial apoptosis and expression of myocardial IR and IRS-1 in chronic heart failure rat models. Mol Med Rep 17:1057-1064 (2018). PubMed: 29115626
- Zhao L et al. Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus. Ther Clin Risk Manag 13:739-750 (2017). PubMed: 28721055